My apologies I have to retract 4 of the 5 countries, it is only approved by the European Commission, not individual countries in the EU. The countries will come over the coming months.
“Today’s marketing authorization the first for an allogeneic stem cell therapy, represents a positive advancement in the treatment of patients with complex perianal fistulas in Crohn’s disease,” said Dr. Asit Parikh, Head of Takeda’s Gastroenterology Therapeutic Area Unit. “We look forward to bringing this much needed treatment option to patients across Europe in the coming months.”
So that is one country, Japan and to be available across EU members with some extra work, bureaucratic I think
. The TiGenix/Takeeda release is here.
http://tigenix.com/wp-content/uploa...nix-Takeda-EC-approval-PR-ENG-FINAL-clean.pdf
The following is from the start of the relevent Mesoblast release found here;
15 December 2017
Mesoblast Grants TiGenix License For Treatment of Fistulae
Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae
New York, USA, Melbourne, Australia and Leuven, Belgium, December 14, 2017 - Mesoblast Limited (ASX: MSB; Nasdaq: MESO) and TiGenix NV (Euronext Brussels and Nasdaq: TIG) today announce that Mesoblast has granted TiGenix exclusive access to certain of its patents to support global commercialization of the adipose-derived mesenchymal stem cell product Cx601 for the local treatment of fistulae. The agreement includes the right for TiGenix to grant sub-licenses to affiliates and third parties, including TiGenix’s current development and commercialization partner ex-United States.
